ClinConnect ClinConnect Logo
Search / Trial NCT07029854

Laser Acupoints Stimulation on Xerostomia Related Chemoradiotherapy for Head and Neck Cancer Patients

Launched by CAIRO UNIVERSITY · Jun 12, 2025

Trial Information

Current as of July 01, 2025

Not yet recruiting

Keywords

ClinConnect Summary

This clinical trial is studying whether using a special type of laser treatment on certain points of the body (called acupoints) can help reduce dry mouth (xerostomia) in patients receiving chemotherapy and radiation therapy for head and neck cancer. Dry mouth is a common side effect during these treatments and can make eating, speaking, and swallowing difficult. The goal is to see if this laser stimulation can provide relief and improve quality of life during cancer treatment.

To take part, patients need to have head and neck cancer and be undergoing combined chemotherapy and radiation therapy. Their salivary glands (which produce saliva) must be intact and working, and they should be medically stable. People with a history of dry mouth before treatment, bleeding problems, or certain other health issues will not be eligible. If accepted, participants will receive laser treatment on specific acupoints and be closely monitored throughout their cancer therapy. This study has not started recruiting yet, but it aims to find new ways to help patients manage the uncomfortable side effects of their cancer treatment.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Chemoradiation therapy
  • Carcinoma in the head and neck area (NPC)
  • Anatomically intact parotid and submandibular glands.
  • All patients will be clinically and medically stable when attending the study.
  • Exclusion Criteria:
  • They had a history of xerostomia;
  • They had suspected or confirmed physical closure of salivary gland.
  • ducts on either side.
  • They had known bleeding disorders.
  • They Were taking heparin or warfarin.
  • They had contraindications for the use of acupuncture at any acupoints.
  • They had history of cerebrovascular accident or spinal cord injury.
  • They had taken any drug or herbal medicine in the past 30 days that could affect salivary function.
  • They were planning to, or ended up taking such a substance during the study.
  • Any therapy that may affect treatment.

About Cairo University

Cairo University, a premier institution in Egypt, is dedicated to advancing medical research and education through innovative clinical trials. With a strong emphasis on improving healthcare outcomes, the university collaborates with various stakeholders to conduct rigorous scientific studies that address critical health challenges. Leveraging its extensive resources and expert faculty, Cairo University aims to contribute valuable insights to the medical community and enhance patient care both locally and globally. Through its commitment to ethical research practices and excellence, the university plays a pivotal role in shaping the future of healthcare in the region.

Locations

Cairo, , Egypt

Patients applied

0 patients applied

Trial Officials

Amal Mohamed Abd El Baky, PhD

Study Chair

Professor, Cairo university

Adel Mahmoud Attia, PhD

Study Director

Lecturer, Zagazig university

Doaa Atef Aly, PhD

Study Director

Lecturer, Cairo university

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported